Stratos Wealth Partners LTD. Sells 4,579 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Stratos Wealth Partners LTD. reduced its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 27.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,974 shares of the company’s stock after selling 4,579 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Recursion Pharmaceuticals were worth $63,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after acquiring an additional 2,026 shares during the period. Farther Finance Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after buying an additional 1,353 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock valued at $53,000 after purchasing an additional 2,387 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $54,000. Finally, San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the first quarter worth approximately $54,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $5.52 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The stock has a market cap of $2.24 billion, a P/E ratio of -3.12 and a beta of 0.91. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The stock’s 50 day simple moving average is $4.89 and its 200 day simple moving average is $6.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company had revenue of $14.75 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter in the prior year, the company earned ($0.39) earnings per share. The firm’s revenue was up 7.2% compared to the same quarter last year. As a group, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $7.00.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.